The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Open accessAbstract
BACKGROUND: Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. METHODS: In this double-blind, randomized trial involving high-risk ambulatory patients with cancer (Khorana score of ≥2, on a scale from 0 to 6, with higher scores indicating a higher risk of venous thromboembolism), we randomly assigned patients without deep-vein thrombosis at screening to receive rivaroxaban (at a dose of 10 mg) or placebo daily for up to 180 days, with screening every 8 weeks. The primary efficacy end point was a composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous thromboembolism and was assessed up to day 180. In a prespecified supportive analysis involving the same population, the same end point was assessed during the intervention period (first receipt of trial agent to last dose plus 2 days). The primary safety end point was major bleeding. RESULTS: Of 1080 enrolled patients, 49 (4.5%) had thrombosis at screening and did not undergo randomization. Of the 841 patients who underwent randomization, the primary end point occurred in 25 of 420 patients (6.0%) in the rivaroxaban group and in 37 of 421 (8.8%) in the placebo group (hazard ratio, 0.66; 95% confidence interval [CI], 0.40 to 1.09; P = 0.10) in the period up to day 180. In the prespecified intervention-period analysis, the primary end point occurred in 11 patients (2.6%) in the rivaroxaban group and in 27 (6.4%) in the placebo group (hazard ratio, 0.40; 95% CI, 0.20 to 0.80). Major bleeding occurred in 8 of 405 patients (2.0%) in the rivaroxaban group and in 4 of 404 (1.0%) in the placebo group (hazard ratio, 1.96; 95% CI, 0.59 to 6.49). CONCLUSIONS: In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period. During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding. (Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Self-citationLyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Self-citationKakkar, A. K., Brenner, B., Dahl, O. E., Eriksson, B. I., Mouret, P., Muntz, J., Soglian, A. G., Pap, Á. F., Misselwitz, F., & Haas, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60880-6 · Cited by 1,070
Self-citationNATURAL HISTORY OF POSTOPERATIVE DEEP-VEIN THROMBOSIS
Kakkar, V. V., Howe, C. T., Flanc, C., & Clarke, M. B. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90002-6 · Cited by 899
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814468 · Cited by 852
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700518 · Cited by 787
Self-citationPrediction of venous thromboembolism in cancer patients
Ay, C., Dunkler, D., Marosi, C., Chiriac, A.-L., Vormittag, R., Simanek, R., Quehenberger, P., Zielinski, C., & Pabinger, I. (2010) · Blood · doi:10.1182/blood-2010-02-270116 · Cited by 772
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Cohen, A. T., Spiro, T. E., Büller, H. R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Spyropoulos, A. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1111096 · Cited by 607
Agnelli, G., Gussoni, G., Bianchini, C., Verso, M., Mandalà, M., Cavanna, L., Barni, S., Labianca, R., Buzzi, F., Scambia, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70232-3 · Cited by 598
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Goldhaber, S. Z., Leizorovicz, A., Kakkar, A. K., Haas, S. K., Merli, G., Knabb, R. M., & Weitz, J. I. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110899 · Cited by 547
Self-citationSemuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Agnelli, G., George, D. J., Kakkar, A. K., Fisher, W., Lassen, M. R., Mismetti, P., Mouret, P., Chaudhari, U., Lawson, F., & Turpie, A. G. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108898 · Cited by 531
Self-citationO'Connell, C. L., Razavi, P., Ghalichi, M., Boyle, S., VASAN, S., Mark, L., Caton, A. M., Duddalwar, V. A., Boswell, W. D., Grabow, K., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04114.x · Cited by 145
Self-citationZwicker, J. I., Liebman, H. A., Bauer, K. A., Caughey, T., Campigotto, F., Rosovsky, R. P. G., Mantha, S. H., Kessler, C. M., Eneman, J. D., Raghavan, V. R., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12163 · Cited by 142
Self-citationvan der Hulle, T., den Exter, P. L., Planquette, B., Meyer, G., Soler, S., Monréal, M., Jiménez, D., Portillo, A. K., O'Connell, C. L., Liebman, H. A., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13172 · Cited by 124
Self-citationNisio, M. D., Lee, A. Y. Y., Carrier, M., Liebman, H. A., & Khorana, A. A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12883 · Cited by 111
Self-citationIncidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Ferrante, N., Tursi, M. D., Iacobelli, S., Cuccurullo, F., Buller, H. R., Feragalli, B., Porreca, E., & Nisio, M. D. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0277 · Cited by 93
Long‐term outcomes of cancer‐related isolated distal deep vein thrombosis: the OPTIMEV study
Galanaud, J. ‐., Sevestre, M., Pernod, G., Genty, C., Richelet, S., Kahn, S. R., Boulon, C., Terrisse, H., Quéré, I., & Bosson, J. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13664 · Cited by 71
Khorana, A. A., Vadhan‐Raj, S., Kuderer, N. M., Wun, T., Liebman, H. A., Soff, G. A., Belani, C. P., O'Reilly, E. M., McBane, R. D., Eikelboom, J. W., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0171 · Cited by 67
Self-citationProphylaxis against Venous Thromboembolism in Ambulatory Patients with Cancer
Connors, J. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1401468 · Cited by 61
Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism
Brenner, B., Bikdeli, B., Tzoran, I., Madridano, O., López-Reyes, R., Suriñach, J. M., Blanco-Molina, Á., Tufano, A., López-Núñez, J. J., Trujillo‐Santos, J., et al. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.04.037 · Cited by 55
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504
Self-citationLyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Self-citationKhan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32658-1 · Cited by 753
Venous thromboembolism in cancer patients: a population-based cohort study
Mulder, F. I., Horváth-Puhó, E., van Es, N., van Laarhoven, H. W. M., Pedersen, L., Moik, F., Ay, C., Büller, H. R., & Sørensen, H. T. (2021) · Blood · doi:10.1182/blood.2020007338 · Cited by 723
Metadata
- Authors
- Khorana, A. A., Soff, G. A., Kakkar, A. K., Vadhan-Raj, S., Riess, H., Wun, T., Streiff, M. B., Garcia, D. A., Liebman, H. A., Belani, C. P., O’Reilly, E. M., Patel, J. N., Yimer, H. A., Wildgoose, P., Burton, P., Vijapurkar, U., Kaul, S., Eikelboom, J., McBane, R., Bauer, K. A., Kuderer, N. M., & Lyman, G. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 720-728
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917722773
- Cited by
- 719
- References
- 23
- FWCI
- 79.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.